Affymax has earned $50m development milestone payment from Takeda Pharmaceutical Company for the US approval of OMONTYS (peginesatide) injection.
The company has also received another $5m milestone payment, which was triggered by the European Medicines Agency (EMA) acceptance of the marketing authorization application.
Peginesatide is currently under review by the EMA for the treatment of symptomatic anemia associated with chronic kidney disease in adult patients on dialysis.
In 2006, Affymax and Takeda entered into a global agreement to collaborate on the development and commercialization of OMONTYS.
Takeda holds an exclusive license to develop and commercialize the product outside the US, while both the companies are working together to co-commercialize OMONTYS in the US.